<DOC>
	<DOCNO>NCT00338091</DOCNO>
	<brief_summary>The primary goal trial evaluate whether optimal antiproteinuric dos benazepril ( ACE inhibitor ) losartan ( ARB ) , compare conventional dos , safely improve long-term renal outcome nondiabetic patient proteinuria chronic renal insufficiency . The second aim compare long-term renal protection benazepril losartan similar clinical setting .</brief_summary>
	<brief_title>Long-Term Renoprotection Optimal Antiproteinuric Doses Benazepril Losartan Chronic Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<criteria>1 . Serum creatinine concentration 1.5 5.0 mg per deciliter ( 133 442 µmol/L ) 2 . Creatinine clearance 20 70 ml per minute per 1.73m2 , variation less 30 percent three month screen evaluation 3. nondiabetic renal disease 4 . Persistent heavy proteinuria ( defined urinary protein excretion 1.0 g per day three month without evidence urinary tract infection overt heart failure [ New York Heart Association class Ⅲ Ⅳ ] ) 1 . Immediate need dialysis 2 . Treatment corticosteroid , non steroidal antiinflammatory drug , immunosuppressive drug 3 . Hyperor hypokalemia ( serum potassium concentration 5.6 mmol per liter more，or 3.5 mmol per liter le ) 4 . Renovascular disease 5 . Myocardial infarction cerebrovascular accident year precede trial 6 . Connectivetissue disease ; obstructive uropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Benazepril</keyword>
	<keyword>Losartan</keyword>
</DOC>